Crescent Innovations Inc. Reports That Inquiries Surrounding Sale of Its Bone Repair Technology Are Increasing
August 29, 2024 08:00 ET
|
Crescent Innovations Inc.
Crescent Innovations Inc. reports that inquires surrounding sale of its bone repair technology are increasing.
DiaMedica Therapeutics Doses First Patient in Phase 1b Clinical Study of DM199 in Patients with Chronic Kidney Disease
February 14, 2019 08:00 ET
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Feb. 14, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, today announced that it has initiated dosing patients with chronic...
DiaMedica Therapeutics Announces Publication of a Paper, “Human Tissue Kallikrein in the Treatment of Acute Ischemic Stroke,” in the Journal Therapeutic Advances in Neurological Disorders
January 22, 2019 07:45 ET
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Jan. 22, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (NASDAQ:DMAC) announces the publication of a paper titled “Human Tissue Kallikrein In The Treatment Of Acute Ischemic...
UPDATE -- DiaMedica Announces FDA Clearance of IND Application To Study DM199 in Patients with Chronic Kidney Disease
January 03, 2019 10:41 ET
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Jan. 03, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (“DiaMedica”) (NASDAQ:DMAC) (TSX-V:DMA) announced today that the U.S. Food and Drug Administration ("FDA") has accepted...
DiaMedica Announces FDA Clearance of IND Application To Study DM199 in Patients with Chronic Kidney Disease
January 03, 2019 07:30 ET
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Jan. 03, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (“DiaMedica”) (NASDAQ:DMAC) (TSX-V:DMA) announced today that the U.S. Food and Drug Administration ("FDA") has accepted...
DiaMedica Therapeutics Has Applied to List its Common Shares on Nasdaq, Announces Share Consolidation
November 12, 2018 16:45 ET
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Nov. 12, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (TSX Venture:DMA) (OTCQB:DMCAF), a clinical stage biopharmaceutical company, announced today that it has applied to list...
DiaMedica Therapeutics Announces Results From Annual General and Special Meeting of Shareholders
November 06, 2018 17:00 ET
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Nov. 06, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (TSX-V:DMA) (OTCQB:DMCAF), a clinical stage biopharmaceutical company, today announced the voting results from its Annual...
DiaMedica Therapeutics Announces the Appointment of Dr. Harry Alcorn Jr. as Chief Medical Officer
September 05, 2018 08:00 ET
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Sept. 05, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company” and “DiaMedica”) (TSX-V:DMA) (OTCQB:DMCAF) announces the recent appointment of Harry Alcorn Jr. Pharm.D. as...
DiaMedica Therapeutics Announces Final Closing of Private Placement
March 29, 2018 18:08 ET
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, March 29, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company” and “DiaMedica”) (TSX-V:DMA) (OTCQB:DMCAF) is pleased to announce the successful completion of the second...
DiaMedica Therapeutics Announces Closing of Private Placement
March 20, 2018 17:40 ET
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, March 20, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company”) (TSX-V:DMA) (OTCQB:DMCAF) is pleased to announce the successful completion of the first closing of a...